Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has a manageable safety profile and robust clinical activity against advanced malignancies. The lowest effective dose for evaluation in further dose‐ranging studies was identified by developing a translational model fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindauer, A, Valiathan, CR, Mehta, K, Sriram, V, de Greef, R, Elassaiss‐Schaap, J, de Alwis, DP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270293/
https://www.ncbi.nlm.nih.gov/pubmed/27863176
http://dx.doi.org/10.1002/psp4.12130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270293/
https://www.ncbi.nlm.nih.gov/pubmed/27863176
http://dx.doi.org/10.1002/psp4.12130

Ejemplares similares